Choi C M, Lerner E A
Boston University School of Medicine, Massachusetts General Hospital and Harvard Medical School, USA.
J Investig Dermatol Symp Proc. 2001 Dec;6(3):175-82. doi: 10.1046/j.0022-202x.2001.00038.x.
Leishmaniasis is a protozoan disease whose diverse clinical manifestations are dependent both on the infecting species of Leishmania and the immune response of the host. Transmission of the disease occurs by the bite of a sand fly infected with Leishmania parasites. Infection may be restricted to the skin in cutaneous leishmaniasis, limited to the mucous membranes in mucosal leishmaniasis, or spread internally in visceral leishmaniasis or kala azar. The overall prevalence of leishmaniasis is 12 million cases worldwide, and the global yearly incidence of all clinical forms approaches 2 million new cases (World Health Organization WHO/ LEISH/200.42, Leishmania/HIV Co-Infection in Southwestern Europe 1990-98: Retrospective Analysis of 965 Cases, 2000). In the last two decades, leishmaniasis, especially visceral leishmaniasis, has been recognized as an opportunistic disease in the immunocompromised, particularly in patients infected with human immunodeficiency virus.
利什曼病是一种原生动物疾病,其多样的临床表现既取决于感染的利什曼原虫种类,也取决于宿主的免疫反应。该疾病通过感染利什曼原虫的白蛉叮咬传播。在皮肤利什曼病中,感染可能局限于皮肤;在黏膜利什曼病中,感染局限于黏膜;在内脏利什曼病或黑热病中,感染则在内脏扩散。利什曼病在全球的总体患病率为1200万例,所有临床类型的全球年发病率接近200万新病例(世界卫生组织WHO/LEISH/200.42,《1990 - 1998年西南欧利什曼原虫/人类免疫缺陷病毒合并感染:965例回顾性分析》,2000年)。在过去二十年中,利什曼病,尤其是内脏利什曼病,已被公认为免疫功能低下者,特别是感染人类免疫缺陷病毒患者中的一种机会性疾病。